Search results
1 company and 9 research reports found for "bionomics"
Company results
- Bionomics
Bionomics is an Australian biotech company focused on developing small molecule products for cancer,...
Sector reports
No sector reports have been found.
Research results
Bionomics
105 combination strategy
Review | Pharmaceutical & Healthcare | 11/08/2011Bionomics is to focus future development of its vascular disrupting agent BNC105 on combinations with chemotherapy, after a review of interim data fro...
Bionomics
BNC210 studies positive
Review | Pharmaceutical & Healthcare | 04/04/2011Bionomics’ investment case is now centred back on the success of the two ongoing BNC105 studies and on its ability to secure attractive partnering d...
Bionomics
2011 - year of change
Update | Pharmaceutical & Healthcare | 06/01/20112011 is set to be a critical year for Bionomics, whose investment case depends on interim analysis of two ongoing Phase II studies of BNC105 and a ten...
Bionomics
Fund sparks bid interest
Review | Pharmaceutical & Healthcare | 17/11/2010Start-up Australia Ventures has put up for sale its 28% interest in Bionomics in the hope of attracting a trade buyer that would use it as a means to ...
Bionomics
BNC210 trials approved
Review | Pharmaceutical & Healthcare | 05/10/2010Bionomics is to start two new Phase Ib studies of its anti-anxiety compound BNC210 and has separately confirmed that enrolment into its two Phase II t...
Bionomics
BCN210 study plans
Review | Pharmaceutical & Healthcare | 25/06/2010Bionomics is selecting doses for two planned Phase Ib studies of its anxiety compound BNC210, which are due to begin enrolment shortly and are expecte...
Bionomics
BCN105 profile raised
Review | Pharmaceutical & Healthcare | 01/04/2010An unexpected setback involving a key competitor coming ahead of a series of presentations at international cancer meetings should help to raise the p...
Bionomics
BNC210 Phase I data
Update | Pharmaceutical & Healthcare | 03/03/2010Final data from an escalating single-dose Phase Ia study of the anxiety/depression compound BNC210 in healthy volunteers show the drug to be well tole...
Bionomics
VDA development plan
Outlook | Pharmaceutical & Healthcare | 23/02/2010The investment case for Bionomics centres on its two lead candidates, BNC105, a vascular disrupting agent in Phase II studies for mesothelioma and kid...
